نتایج جستجو برای: ambrisentan

تعداد نتایج: 197  

2008
Nazzareno Galiè Hossein A. Ghofrani Michael D. McGoon Vallerie V. McLaughlin Michael J. Gerber

Nazzareno Galiè, MD; Horst Olschewski, MD; Ronald J. Oudiz, MD; Fernando Torres, MD; Adaani Frost, MD; Hossein A. Ghofrani, MD; David B. Badesch, MD; Michael D. McGoon, MD; Vallerie V. McLaughlin, MD; Ellen B. Roecker, PhD; Michael J. Gerber, MD; Christopher Dufton, PhD; Brian L. Wiens, PhD; Lewis J. Rubin, MD; for the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Pl...

2016

The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1):  ambrisentan (LETAIRIS®) oral;  bosentan (TRACLEER®) oral;  epoprostenol sodium (e.g., FLOLAN®) continuous IV infusion;  Iloprost (VENTAVIS®) Inhalation via nebulizer;  macitentan (OPSUMIT®) oral;  riociguat (ADEMPAS®) oral;  sildenafil citrate (e.g., REV...

Journal: :Acta Crystallographica Section A Foundations and Advances 2017

Journal: :Proceedings for Annual Meeting of The Japanese Pharmacological Society 2018

2014
Daniel Radiloff Yulin Zhao Alina Boico Gert Blueschke Gregory Palmer Andrew Fontanella Mark Dewhirst Claude A. Piantadosi Robert Noveck David Irwin Karyn Hamilton Bruce Klitzman Thies Schroeder

Rapid ascent to high altitude causes illness and fatigue, and there is a demand for effective acute treatments to alleviate such effects. We hypothesized that increased oxygen delivery to the tissue using a combination of a hypertensive agent and an endothelin receptor A antagonist drugs would limit exercise-induced fatigue at simulated high altitude. Our data showed that the combination of 0.1...

2013
Pranay Wal Ankita Wal Shweta Tripathi Awani K Rai

Increasing numbers of experimental investigations and recently also of clinical trials strongly suggest an integral involvement of the endothelin (ET) system in the pathophysiology of a variety of disease states, mainly of the cardiovascular system.Ambrisentan (LU 208075)approved by the US Food and Drug Administration in 2007, a selective ETA-receptor antagonist, is an orally active diphenyl pr...

Journal: :Journal of gastrointestinal and liver diseases : JGLD 2011
Carl Eriksson Anders Gustavsson Thomas Kronvall Curt Tysk

Bosentan is an endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension. Mild liver reactions occur in about 10% of treated patients but severe hepatotoxicity is rare. We present clinical data and treatment outcome of a severe drug induced liver injury due to bosentan in a patient with non-cirrhotic portopulmonary hypertension. After 18 months of uncomplicated th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید